-KG, also named 2-oxoglutarate, is a cofactor for 2-oxoglutarate-dependent dioxygenases (2-OGDDs), which catalyze hydroxylation reactions on diverse substrates
AstraZenecas recent FDA approval for Baxfendy feels like another reminder that big pharma is still doubling down on chronic disease spaces where the commercial opportunity is large, but the operational and development complexity is also very high
Current projections suggest the following timeline: Phase 3 trials complete around 2026 Regulatory submissions occur shortly after Potential approval may occur between 2027 and 2028 if results remain favorable (GLP3 Planner) These timelines depend heavily on: Final safety data Regulatory review Post-trial analyses Drug development is inherently uncertain, and unexpected findings can delay approval
Yes, copper peptides are safe to use on active acne
Were taking apple cider vinegar and they did improve symptoms of their gut disorder
Small changes like this make the difference between someone who hits their daily fluid target and someone who forgets